Feed NBIX
NB

Neurocrine Biosciences

NBIX · NASDAQ

$146.23 -4.11% (-$6.26)
1M -4.38%
Market Cap $15.3B
P/E Ratio 21.64x
Div. Yield -
ROE 21.13%

Bulios Fair Price

$145.71

0.4% downside

Trenutna cena

$146.23

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica NBIX trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Moderate
5/9
Valuation
58 /100
Fair
PEG 0.79x
P/E 21.64x
P/B 4.13x
Growth
100 /100
Growing
FCF growth 32.36%
EPS growth 44.12%
Book val. growth 23.96%
Profitability
98 /100
Strong
Op. margin 23.38%
Gross margin 97.97%
FCF margin 25.80%
Quality
80 /100
Excellent
ROA 13.16%
ROIC 13.20%
Asset turnover 0.63x
Debt
99 /100
Low
Int. coverage 300.28x
Debt/Equity 0.11x
Net debt/EBITDA 0.08x
Stability
86 /100
Stable
EPS volatility 12.76%
Beta 0.38x
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o NBIX
Online

O podjetju

Neurocrine Biosciences, Inc. is an American biotechnology company headquartered in San Francisco, California. The company focuses on the development of drugs for the treatment of neurological and endocrine disorders. Their main products include medications for the treatment of sleep disorders, movement disorders, and endocrine disorders such as diabetes. Neurocrine Biosciences specializes in research and development of new drug formulations targeting specific biological targets related to neurological and endocrine diseases. The company is known for its innovative drugs and technologies that help patients with these serious conditions. Shares of Neurocrine Biosciences, Inc. are publicly traded on the NASDAQ stock exchange.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Kyle W. Gano

Employees

2,500

Headquarters

San Diego

Prihajajoči dogodki

27 OKT.

Earnings

Upcoming earnings report

38d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.